Peter A. Thompson - 28 Jan 2026 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CRVS
Reported as of: 28 Jan 2026
Net transaction value: +$1,119,374
SEC form: 4
Accepted by SEC: 30 Jan 2026, 18:39:04 UTC
Prior SEC filing: 29 Dec 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter A. Thompson

Key filing fact

Peter A. Thompson filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 30 Jan 2026.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
26 reported transactions and 13 derivative rows are listed below.
Accepted by SEC: 30 Jan 2026, 18:39.

Change

Previous filing in this sequence was filed on 29 Dec 2025.
Current net transaction value: +$1,119,374.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001357522 Primary reporting owner

Thompson Peter A.

Relationship: Director, 10%+ Owner
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Peter A. Thompson
Signature date: 30 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVS transaction

Common Stock

Options Exercise

Transaction value: $450,000
Shares: +30,000
Change %
Price: $15.00
Shares after: 30,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $145,500
Shares: +15,000
Change %: +50%
Price: $9.70
Shares after: 45,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $187,500
Shares: +15,000
Change %: +33%
Price: $12.50
Shares after: 60,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $54,150
Shares: +15,000
Change %: +25%
Price: $3.61
Shares after: 75,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $30,000
Shares: +15,000
Change %: +20%
Price: $2.00
Shares after: 90,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $49,050
Shares: +15,000
Change %: +17%
Price: $3.27
Shares after: 105,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $41,100
Shares: +15,000
Change %: +14%
Price: $2.74
Shares after: 120,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $39,000
Shares: +15,000
Change %: +12%
Price: $2.60
Shares after: 135,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $14,848
Shares: +15,000
Change %: +11%
Price: $0.9899
Shares after: 150,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $14,475
Shares: +15,000
Change %: +10%
Price: $0.9650
Shares after: 165,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $37,350
Shares: +15,000
Change %: +9.1%
Price: $2.49
Shares after: 180,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $24,600
Shares: +15,000
Change %: +8.3%
Price: $1.64
Shares after: 195,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS transaction

Common Stock

Options Exercise

Transaction value: $31,800
Shares: +15,000
Change %: +7.7%
Price: $2.12
Shares after: 210,000
Date: 28 Jan 2026
Ownership: Direct
Footnotes: F1

CRVS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,609,091
Date: 28 Jan 2026
Ownership: See Footnotes
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -30,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $15.00
Footnotes: F1, F4

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $9.70
Footnotes: F1, F5

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $12.50
Footnotes: F1, F6

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $3.61
Footnotes: F1, F7

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.00
Footnotes: F1, F8

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $3.27
Footnotes: F1, F9

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.74
Footnotes: F1, F10

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.60
Footnotes: F1, F11

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.9899
Footnotes: F1, F12

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.9650
Footnotes: F1, F13

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.49
Footnotes: F1, F14

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $1.64
Footnotes: F1, F15

CRVS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $2.12
Footnotes: F1, F16

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 16 footnotes

Footnote F1

Pursuant to an agreement with OrbiMed Advisors LLC ("OrbiMed Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F2

These securities are held of record by OPI V. GP V is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.

Footnote F3

Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Footnote F4

The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.

Footnote F5

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F6

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F7

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F8

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

Footnote F9

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F10

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F11

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

Footnote F12

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F13

The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Footnote F14

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F15

The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Footnote F16

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.